Press Releases

Jazz Pharmaceuticals Investor & Media Relations
Investors: investorinfo@jazzpharma.com
Media: mediainfo@jazzpharma.com
Ireland, +353 1 634 7892
U.S., +1 650 496 2800
Keyword Search
 
2014 | 2013 | 2012 | 2011
DateTitle  
03/31/14Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease
Defitelio®▼ (defibrotide) Launch Announced During the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 2014 DUBLIN and VILLA GUARDIA, Italy, March 31, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of Defitelio®▼ (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive disease (severe V... 
Download PDFPrinter Friendly Version
02/26/14Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
DUBLIN, Feb. 26, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.  Cowen and Company 34th Annual Healthcare Conference in Boston, MA on Wednesday, March 5, 2014 at 8:00 a.m. EST / 1:00 p.m. GMT.  Matt Young, senior vice president, corporate development, will provide an overview of the company and a business and financial update.  The company recently announced t... 
 Printer Friendly Version
02/25/14Jazz Pharmaceuticals Announces Management Change
Chief Financial Officer Kathryn Falberg to Step Down; Matthew Young Appointed CFO DUBLIN, Feb. 25, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Kathryn Falberg, executive vice president and chief financial officer (CFO), has resigned from the company, effective March 9, 2014, to pursue other interests.  Ms. Falberg will serve as a consultant to Jazz Pharmaceuticals during a transition period. Matthew Young, senior vice president of corporate development... 
 Printer Friendly Version
02/25/14Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2013 Financial Results
Company Reports Total Revenues of $872 Million in 2013 Driven by Strong Sales of Xyrem and Erwinaze Adjusted EPS of $6.31 and GAAP EPS of $3.51 in 2013 DUBLIN, Feb. 25, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter ended December 31, 2013 and provided financial guidance for 2014. "2013 was an outstanding year as we delivered strong top-line growth, generated significant cash flow and executed on ou... 
 Printer Friendly Version
02/21/14Jazz Pharmaceuticals plc Completes Tender Offer For Gentium S.p.A. Shares
Approximately 98 percent of outstanding Gentium ordinary shares and American Depositary Shares tendered DUBLIN, Feb. 21, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the subsequent offering period of the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares ("ADSs") of Gentium S.p.A. (Nasdaq: GENT) for $57.00 per share and per ADS (without duplication for ordinary sh... 
 Printer Friendly Version
02/11/14Jazz Pharmaceuticals to Report 2013 Fourth Quarter and Full Year Financial Results on February 25, 2014
DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2013 fourth quarter and full year financial results on Tuesday, February 25, 2014, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to provide a business and financial update and discuss fourth quarter and full year 2013 financial results and provide guidance for 2014... 
 Printer Friendly Version
02/11/14Jazz Pharmaceuticals Announces U.S. Commercial Availability Of Versacloz™ (clozapine, USP) Oral Suspension
First liquid formulation clozapine for treatment-resistant schizophrenia DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz™ (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.   "We are pleased to offer patients with treatmen... 
 Printer Friendly Version
02/10/14Jazz Pharmaceuticals Breaks Ground On New Manufacturing And Development Facility In Ireland
DUBLIN, Feb. 10, 2014 /PRNewswire/ --Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced that it has commenced construction of a manufacturing and development facility to be located on a 17-acre site in Monksland, County Roscommon, approximately 75 miles east of the company's Dublin headquarters. This is the first manufacturing facility to be built by Jazz Pharmaceuticals.   "Today marks a milestone for Jazz Pharmaceuticals as we break ground in Ireland and begin, for the first time, construc... 
 Printer Friendly Version
01/23/14Jazz Pharmaceuticals plc Announces Minimum Tender Condition Exceeded During Initial Offering Period For Gentium S.p.A. Shares
Approximately 79 percent of outstanding Gentium ordinary shares and American Depositary Shares tendered Subsequent offering period commenced to permit additional shares to be tendered DUBLIN, Jan. 23, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the initial offering period in the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares ("ADSs") of Gentium S.p.A. (Nasdaq: GENT) f... 
 Printer Friendly Version
01/13/14Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness
Terms include $125 million upfront payment in cash plus a potential of up to $272 million in milestone payments Investor conference call to be held today, January 13 at 8:30 AM EST/1:30 PM GMT DUBLIN, Jan. 13, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Aerial BioPharma, LLC (Aerial) today announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development ... 
Download PDFPrinter Friendly Version
01/06/14Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
DUBLIN, Jan. 6, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Bruce C. Cozadd, chairman and chief executive officer, will provide an overview of the company and provide a business and financial update at the conference on Monday, January 13, 2014 at 10:00 a.m. PST / 6:00 p.m. GMT. A live audio webcast of the presentation ma... 
 Printer Friendly Version